tremelimumab-actl
| Brand name | Imjudo |
|---|---|
| Active ingredient | tremelimumab-actl |
| Strength | 25MG/1.25ML (20MG/ML) |
| Dosage form | Injection |
| Route | Intravenous |
| Modality | Biologic |
| FDA approval | October 2022 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.